Clinical Trial Update: BAY88-8223, Dose Finding Study in Patients With HRPC [Phase 2]

View source ↗

Summary

Phase 2 dose-finding trial of BAY88-8223 in hormone-refractory prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasm Metastasis
• Prostate Cancer

Drugs mentioned

• BAY88-8223

Snippet

Sponsor: Bayer | Conditions: Prostate Cancer, Neoplasm Metastasis | Phase 2 | Status: COMPLETED